Laura D'Erasmo retweeted
Lilly's Mounjaro (tirzepatide), a GIP/GLP-1 dual agonist, demonstrated CV protection in landmark head-to-head trial! Wow! Big news! Can’t wait to see the results at EASD @CMHC_CME @nationallipid @ASPCardio investor.lilly.com/news-rele…
Laura D'Erasmo retweeted
#Hypertriglyceridemia is independently associated with risk of atherosclerotic events, even when LDL-cholesterol levels appear controlled. This #INTERASPIRE study determined the frequency of HTG and residual combined dyslipidemia and their related factors in patients with coronary heart disease (CHD) from 13 countries across six World Health Organization (WHO) regions.
Read more: bit.ly/4kDPQSn
Laura D'Erasmo retweeted
“Lipid-Lowering Therapy and Cardiovascular Prevention in Elderly”
A narrative review on one of the great challenges of our times.
rdcu.be/el2zv
Laura D'Erasmo retweeted
New @lipidjournal article!📄 Check out our latest open access article on lomitapide treatment in patients with HoFH. Read it now👉ow.ly/cAV150VvTs5
Laura D'Erasmo retweeted
Authors: Marcello Arca, MD, @Lauraderasmo, Marina Cuchel, MD, PhD, Dirk Blom, PhD, Jaimini Cegla, PhD, FRCPath, P. Barton Duell, MD, @rauldsf_santos, Sallyann O'Brien, PhD
Laura D'Erasmo retweeted
Approximately 1 in 5 patients with possible FH who received any form of outreach as part of a QI program had a meaningful change in the management. Various process factors resulted in improved care. ow.ly/Ei1l50VhJg0 @dramitkhera
Laura D'Erasmo retweeted
📣 Clopidogrel outperforms aspirin as chronic monotherapy after PCI - better ischemic protection without increasing bleeding risk 👨⚕️💊
💥 P2Y12 inhibitors strike again! 💥
📌 SMART-CHOICE 3 is now online in @TheLancet 👉 thelancet.com/journals/lance…
@vlgmrc #Cardiology #ACC25
Laura D'Erasmo retweeted
Delighted to have presented the first Phase 2 trial of solbinsiran a siRNA targeting ANGPTL3 a key regular of Triglyceride metabolism. Despite ldl lowering patients with high TG have a high residual risk of CVD.
Laura D'Erasmo retweeted
The EAS FHSC is the largest only global registry of FH. I conceived the idea in 2015 and with a few colleagues started this. 10 years on it’s really starting to deliver important insights . Great editorial
Management of obesity in patients living with heterozygous familial hypercholesterolaemia: read the editorial in #EHJ!
academic.oup.com/eurheartj/a…
#obesity #cardiotwitter #EHJ @ESC_journals @escardio
Lipid lowering drugs in special population: focus on kidney disease. @Arca_Lab_
@Tramontano_D @_SimoneBini_
pubmed.ncbi.nlm.nih.gov/4010…
atherosclerosis-journal.com/…
Our latest effort is the result of an international collaboration focused on understanding the consequences of hypertriglyceridemia. #triglycerides #kidneydisease
@ATHjournal @_SimoneBini_
Laura D'Erasmo retweeted
Why some heavy drinkers don't develop cirrhosis ? The answer is in the genes.
This great article summarizes the hallmark research hits implicating PNPLA3 gene variations and individual susceptibility to alcohol-related cirrhosis.
t.ly/os6Rf
Laura D'Erasmo retweeted
Wear red to be seen, to be counted, to be heard, to make an impact. At Atherosclerosis we wear red every day #WearRedDay
@GoRedForWomen #GoRedforWomen #nationalgoredday @American_Heart @society_eas @atherosociety
Laura D'Erasmo retweeted
Spotted in the very first EAS-LIPRA newsletter 📬 Great contribution @brettsmansfield! Can’t wait to read the preliminary results of your investigation on Lp(a) within African populations @society_eas #LIPRA #EASSoMe
Our last effort is now available on @ATHjournal. Understanding the differences in clinical and therapeutic management for men and women. @j_rvl @kiaretta21 @arturocesaro @Tramontano_D atherosclerosis-journal.com/…
Laura D'Erasmo retweeted
The role of lipids in cardiovascular disease is well established through epidemiological studies; however, the underlying pathophysiological mechanisms remain largely unknown. Numerous recent studies focus on the deleterious impact of lipids on cardiovascular health.
In this lecture, Prof. Jan Borén presents a state-of-the-art overview of current knowledge in the field: eas.to/OpenNov24 @ProfKausikRay @KatiOorni





























